Related Experiment Video

Updated: Dec 31, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.4K

Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone

T A Meléndez1, A Huanosta-Gutiérrez1, C Barriga-Montoya1

  • 1School of Medicine. Department of Physiology, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

Pflugers Archiv : European Journal of Physiology
|January 4, 2020
PubMed

Insights

Dronedarone and amiodarone interact differently with the Kv10.1 (KCNH1) channel, a target in tumor development. Dronedarone acts as an open-pore blocker, binding independently from amiodarone.

Area of Science:

  • Biophysics
  • Molecular Pharmacology
  • Ion Channel Physiology

Background:

  • Kv10.1 (Eag1, KCNH1) is a human potassium channel implicated in tumor progression.
  • Dronedarone is an antiarrhythmic drug derived from amiodarone, with modifications to reduce side effects.
  • Previous studies reported amiodarone's interaction with Kv10.1.

Purpose of the Study:

  • To investigate the interaction of dronedarone with the Kv10.1 channel.
  • To compare the inhibitory mechanisms of dronedarone and amiodarone on Kv10.1.
  • To elucidate the binding sites and functional effects of these drugs on Kv10.1.

Main Methods:

  • Electrophysiological recordings (e.g., patch-clamp) to study Kv10.1 channel function.
  • Voltage-clamp analysis to characterize drug-channel interactions.
  • Comparison of drug effects on channel gating and ion conductance.

Main Results:

  • Dronedarone exhibits a distinct inhibitory profile on Kv10.1 compared to amiodarone.
  • Dronedarone appears to function as an open-pore blocker, whereas amiodarone inhibits from both open and closed states.
  • The drugs bind to independent, non-overlapping sites on the Kv10.1 channel.
  • Dronedarone does not inhibit the Cole-Moore shift, unlike amiodarone.

Conclusions:

  • Dronedarone and amiodarone possess fundamentally different mechanisms of Kv10.1 channel inhibition.
  • Despite structural similarities, their distinct binding modes and functional effects highlight unique pharmacological profiles.
  • These findings contribute to understanding the channelopathies and developing targeted therapies for Kv10.1-associated conditions.
Keywords:
AmiodaroneCole-Moore shiftDronedaroneEag1Kv10.1Potassium channels

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.7K
Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.2K

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.6K
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.5K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
560
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
533